1. Reinert M, Fritze D, Nguyen T. Mental Health America: The State of Mental Health in America 2022. Available at https://mhanational.org/issues/state-mental-health-america. Last accessed January 15, 2024.
2. Centers for Disease Control and Prevention. Smokeless Tobacco Use in the United States. Available at https://www.cdc.gov/tobacco/data_statistics/fact_sheets/smokeless/use_us/index.htm. Last accessed January 15, 2024.
3. National Alliance on Mental Illness. Mental Health by the Numbers. Available at https://www.nami.org/mhstats. Last accessed January 15, 2024.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text revision. Washington, DC: American Psychiatric Association; 2022.
6. U.S. Food and Drug Administration. Rural Tobacco Use: Research and Interventions. Available at https://www.fda.gov/media/133281/download. Last accessed January 15, 2024.
7. National Institute of Mental Health. Bipolar Disorder. Available at https://www.nimh.nih.gov/health/topics/bipolar-disorder. Last accessed January 15, 2023.
8. Nurnberger JL, Gershon ES. The genetics of affective disorders. In: Friedman E (ed). Depression and Antidepressants and Implications for Cause and Treatment. New York, NY: Raven Press; 1983: 75-98.
9. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics. 2006;47(1):1-7.
10. American Cancer Society. Health Risks of Smokeless Tobacco. Available at https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/smokeless-tobacco.html. Last accessed January 15, 2024.
11. Lunell E, Bergström M, Antoni G, Långström B, Nordberg A. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharmacol Ther. 1996;59(5):593-594.
13. LexiComp Online. Available at https://online.lexi.com. Last accessed January 15, 2024.
14. American Dental Association. ADA/PDR Guide to Dental Therapeutics. 5th ed. Chicago, IL: American Dental Association; 2009.
15. Couch ET, Chaffee BW, Gansky SA and Walsh MM. The changing tobacco landscape: what dental professionals need to know. J Am Dent Assoc. 2016;147(7):561-9.
16. Mental Health America. Depression. Available at https://www.mhanational.org/conditions/depression. Last accessed January 15, 2024.
17. Lee B, Wang Y, Carlson SA, et al. National, state-level, and county-level prevalence estimates of adults aged ≥18 years self-reporting a lifetime diagnosis of depression—United States, 2020. MMWR. 2023;72:644–650.
19. Al Feghali KA, Ghanem AI, Burmeister C, et al. Impact of smoking on pathological features in oral cavity squamous cell carcinoma. J Cancer Res Ther. 2019;15(3):582-588.
20. American Dental Association. Tobacco Use and Cessation. Available at https://www.ada.org/en/member-center/oral-health-topics/tobacco-use-and-cessation. Last accessed January 15, 2024.
21. Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(2):e5-e31.
22. Gursky TM, Haight R, Hardwig J, et al. Institute for Clinical Systems Improvement. Adult Depression in Primary Care. 17th ed. Available at https://www.icsi.org/wp-content/uploads/2019/01/Depr.pdf. Last accessed January 15, 2024.
23. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Publishing, Inc.; 2010. (Reaffirmed October 31, 2015.)
25. Ouanounou A, Ng K. Medical management, orofacial findings, and dental care for the client with major depressive disorder. Can J Dent Hyg. 2019;53(3):172-177.
26. Randall JR, Walld R, Finlayson G, Sareen J, Martens PJ, Bolton JM. Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatry. 2014;59(10):531-538.
27. American Association of Suicidology. Facts and Statistics. Available at https://suicidology.org/facts-and-statistics. Last accessed January 15, 2024.
29. Anxiety and Depression Association of America. Anxiety Disorders: Facts and Statistics. Available at https://adaa.org/understanding-anxiety/facts-statistics. Last accessed January 15, 2024.
30. Centers for Disease Control and Prevention. Symptoms of Generalized Anxiety Disorder Among Adults: United States, 2019. Available at https://www.cdc.gov/nchs/products/databriefs/db378.htm. Last accessed January 15, 2024.
31. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439.
32. Doggrell SA. Which is the best primary medication for long-term smoking cessation—nicotine replacement therapy, bupropion or varenicline? Expert Opin Pharmacother. 2007;8(17):2903-2915.
33. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
34. Anxiety and Depression Association of America. Clinical Practice Review for GAD. Available at https://adaa.org/resources-professionals/practice-guidelines-gad. Last accessed January 15, 2024.
35. Zhong Z, Zhao S, Zhao Y, Xia S. Combination therapy of varenicline and bupropion in smoking cessation: a meta-analysis of the randomized controlled trials. Compr Psychiatry. 2019;95:152125.
36. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184.
37. Marques L, Robinaugh DJ, LeBlanc NJ, Hinton D. Cross-cultural variations in the prevalence and presentation of anxiety disorders. Expert Rev Neurother. 2011;11(2):313-322.
38. Craske MG, Tsao JC. Assessment and treatment of nocturnal panic attacks. Sleep Med Rev. 2005;9(3):173-184.
39. Katerndahl DA. Chest pain and its importance in patients with panic disorder: an updated literature review. Prim Care Companion J Clin Psychiatry. 2008;10(5):376-383.
40. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF 3rd. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. Focus. 2014;12(3):347-358.
41. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-192.
42. Melaragno AJ. Pharmacotherapy for anxiety disorders: from first-line options to treatment resistance. Focus (Am Psychiatr Publ). 2021;19(2):145-160.
43. Prochaska JO, Redding CA, Evers KE. The transtheoretical model and stages of change. In: Glanz K, Rimer BK, Viswanath K (eds). Health Behavior and Health Education. 4th ed. San Francisco, CA: Jossey-Bass; 2008: 97-121.
44. Global Drug Survey. Global Drug Survey: 2020 Executive Summary. Available at https://www.globaldrugsurvey.com/wp-content/uploads/2021/01/GDS2020-Executive-Summary.pdf. Last accessed January 15, 2024.
45. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
46. Stinson FS, Dawson DA, Chou SP, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007;37(7):1047-1059.
47. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
48. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1-25.
49. Forbes D, Bisson JI, Monson CM, Berliner L. Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies. 3rd ed. New York, NY: Guilford Press; 2020.
50. Nygaard E, Wentzel-Larsen T, Hussain A, Heir T. Family structure and posttraumatic stress reactions: a longitudinal study using multilevel analyses. BMC Psychiatry. 2011;11:195.
51. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder: PTSD Treatments. Available at https://www.apa.org/ptsd-guideline/treatments. Last accessed January 15, 2024.
52. Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend. 2005;80(2):147-159.
53. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(2):1479-1494.
54. National Institute of Mental Health. Schizophrenia. Available at https://www.nimh.nih.gov/health/publications/schizophrenia. Last accessed January 15, 2024.
56. National Alliance on Mental Illness. Types of Medication. Available at https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication. Last accessed January 15, 2024.
57. National Alliance on Mental Illness. Tardive Dyskinesia. Available at https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Last accessed January 15, 2024.
58. Collingwood J. Coping with Atypical Antipsychotic Side Effects. Available at https://psychcentral.com/lib/coping-with-atypical-antipsychotic-side-effects. Last accessed January 15, 2024.
59. Grotenhermen F, Russo E (eds). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghampton, NY: The Hathworth Press; 2002.
60. Little JW, Miller CS, Rhodus NL. Dental Management of the Medically Compromised Patient. 10th ed. St. Louis, MO: Mosby Elsevier; 2023.
61. Patton L, Glick M. The ADA Practical Guide to Patients with Medical Conditions. 2nd ed. Hoboken, NJ: John Wiley and Sons; 2016.
62. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry. 2004;184:470-476.
63. Hannah K, Marie K, Olaf H, et al. The global economic burden of health anxiety/hypochondriasis: a systematic review. BMC Pub Health. 2023; 23:2237.
64. Tomar BI, Bhatia NK, Kumar P, Bhatia MS, Shah RJ. The psychiatric and dental interrelationship. Delhi Psychiatry Journal. 2011;14(1):138-142.
65. John Hopkins Medicine. Trigeminal Neuralgia. Available at https://www.hopkinsmedicine.org/health/conditions-and-diseases/trigeminal-neuralgia. Last accessed January 15, 2024.
66. American Society of Addiction Medicine. Definition of Addiction. Available at https://www.asam.org/quality-care/definition-of-addiction. Last accessed January 15, 2024.
67. Yaksh T, Wallace M. Opioids, analgesia, and pain management. In: Brunton L, Hilal-Dandan R, Knollmann BC (eds). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill; 2017: 355-386.
68. Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend. 2007;87(1):98-102.
69. National Cancer Institute. Cancer Pain. Available at https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq. Last accessed January 15, 2024.
70. U.S. Food and Drug Administration. Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). Available at https://www.accessdata.fda.gov/drugsatfda_docs/rems/ERLA_opioids_2015.06.26_REMS_document.pdf. Last accessed January 15, 2024.
72. Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741-1748.
73. Keyes KM, Rutherford C, Hamilton A, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alc Dep Rep. 2022;3:100052.
74. Centers for Disease Control and Prevention. Adolescent and School Health: High-Risk Substance Use Among Youth. Available at https://www.cdc.gov/healthyyouth/substance-use/index.htm. Last accessed January 15, 2024.
75. McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction. 2007;102(12):1920-1930.
76. The Partnership for a Drug-Free America. 2012 Partnership Attitude Tracking Study: Teens and Parents. Available at https://drugfree.org/wp-content/uploads/2013/04/PATS-2012-FULL-REPORT2.pdf. Last accessed January 15, 2024.
77. Reynolds WR, Schwarz ES. Dentists’ current and optimal opioid prescribing practices: a proactive review. Mo Med. 2019;116(5):347-350.
78. Nack B, Haas SE, Portnof J. Opioid use disorder in dental patients: the latest on how to identify, treat, refer and apply laws and regulations in your practice. Anesth Prog. 2017;64(3):178-187.
79. American Dental Association. ADA Announces New Policy to Combat Opioid Epidemic: Policy Supports Mandates on Opioid Prescribing and Continuing Education. Available at https://www.ada.org/en/about/press-releases/2018-archives/american-dental-association-announces-new-policy-to-combat-opioid-epidemic. Last accessed January 15, 2024.
80. McFarland KK, Giannini PJ, Fung EYK. Addiction and Oral Health Care. Available at https://decisionsindentistry.com/article/addiction-oral-health-care. Last accessed January 15, 2024.
81. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130(1-3):216-221.
82. Drug Enforcement Administration. Benzodiazepines. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/benzo.pdf. Last accessed January 15, 2024.
83. Weissheimer T, Schwengber HE, Gerzson AS, Neto AM. Benzodiazepines for conscious sedation in the dental office. Stomatos. 2016; 22(42).
84. O’Keefe Osborn C. How Long Does Withdrawal From Benzodiazepines Last? Available at https://www.verywellmind.com/benzodiazepine-withdrawal-4588452. Last accessed January 15, 2024.
86. Schuckit MA. Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment. 6th ed. New York, NY: Springer; 2010.
87. Sullivan MA, Rudnik-Levin F. Attention deficit/hyperactivity disorder and substance abuse: diagnostic and therapeutic considerations. Ann NY Acad Sci. 2001;931:251-270.
88. National Institute on Alcohol Abuse and Alcoholism. Alcohol Facts and Statistics. Available at https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics. Last accessed January 15, 2024.
89. Moses S. Lab Markers of Malnutrition. Available at https://fpnotebook.com/Pharm/Lab/LbMrkrsOfMlntrtn.htm. Last accessed January 15, 2024.
90. Van den Berg H, van der Gaag M, Hendriks H. Influence of lifestyle on vitamin bioavailability. Int J Vitam Nutr Res. 2002;72(1):53-59.
91. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol Alcohol. 2000;35(1):2-7.
92. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121-130.
93. Vertava Health. Bone Marrow Suppression from Alcohol Abuse. Available at https://vertavahealth.com/alcohol/bone-marrow-suppression. Last accessed January 15, 2024.
94. Ghosh A, Berger I, Remien CH. The role of alcohol consumption on acetaminophen induced liver injury: implications from a mathematical model. J Theor Biol. 2021;519:110559.
96. U.S. Food and Drug Administration. Acetaminophen Prescription Combination Drug Products with More than 325 mg: FDA Statement: Recommendation to Discontinue Prescribing and Dispensing. Available at https://wayback.archive-it.org/7993/20170406123735/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm381650.htm. Last accessed January 15, 2024.
97. Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2012;10(4):487-492.
98. Grotenhermen F. Review of therapeutic effects. In: Grotenhermen F, Russo E (eds). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. New York, NY: Routledge; 2002: 123-142.
99. Kuffner EK, Green JL, Bogdan GM, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients: a multicenter randomized study. BMC Med. 2007;30:13.
100. Ribeiro LIG, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Primary Care Respiratory Medicine. 2016;26:16071.
101. Cornelius ME, Loretan CG, Jamal A, et al. Tobacco product use among adults—United States, 2021. MMWR. 2023;72(18):475-483.
102. Portillo KM, Sanderson TR, Gurenlian J. Oral Health Care for Marijuana Users. Available at https://decisionsindentistry.com/article/oral-health-care-marijuana-users. Last accessed February 12, 2021.
103. Joshi S, Ashley M. Cannabis: a joint problem for patients and the dental profession. Br Dent J. 2016;220(11):597-601.
104. Ahrens AGMS, Bressi T. Marijuana as promoter for oral cancer? More than a suspect. Addictive Disorders & Their Treatment. 2007;6(3):117-119.
105. Wong LS, Green HM, Feugate JE, Yadav M, Nothnangel EA, Martins-Green M. Effects of “second-hand” smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling. BMC Cell Biol. 2004;5(1):13.
106. Faustino ISP, Gonzalez-Arriagada WA, Cordero-Torres K, Lopes MA. Candidiasis of the tongue in cannabis users: a report of 2 cases. Gen Dent. 2020;68(5):66-68.
107. Centers for Disease Control and Prevention. Lung Cancer: What Are the Risk Factors for Lung Cancer? Available at https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm. Last accessed January 15, 2024.
108. Centers for Disease Control and Prevention. Tobacco Use by Geographic Region. Available at https://www.cdc.gov/tobacco/disparities/geographic/index.htm. Last accessed January 15, 2024.
109. National Institute on Drug Abuse. Cocaine Research Report. Available at https://www.drugabuse.gov/publications/research-reports/cocaine/what-cocaine. Last accessed January 15, 2024.
110. Ries RK, Fiellin DA, Miller SC, Saitz R. Principles of Addiction Medicine. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2018.
111. Burnett LB. Cocaine Toxicity. Available at https://emedicine.medscape.com/article/813959-overview. Last accessed January 15, 2024.
112. Chapparro-Gonzalez NT, Fox-Delgado MA, Pineda-Chaparro RT, Perozo-Ferrer BI, Díaz-Amell AR, Torres V. Oral and maxillofacial manifestations in patients with drug addiction. Odontoesstomatologia. 2018;20(32):24-31.
113. Teoh L, Moses G, McCullough MJ. Oral manifestations of illicit drug use. Aust Dent J. 2019;64(3):213-22.
114. Nassar P, Ouanounou A. Cocaine and methamphetamine: pharmacology and dental implications. Can J Dent Hyg. 2020;54(2):75-82.
115. National Institute on Drug Abuse. Methamphetamine Research Report. Available at https://nida.nih.gov/publications/research-reports/methamphetamine/overview. Last accessed January 15, 2024.
116. Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoactive Drugs. 2000;32(2):137-141.
117. American Dental Association. Methamphetamine. Available at https://www.ada.org/en/resources/research/science-and-research-institute/oral-health-topics/methamphetamine. Last accessed January 15, 2024.
1. Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: a report of the American Dental Association. JADA. 2017;148(10):P712-P727. Available at https://jada.ada.org/article/S0002-8177(17)30701-8/fulltext?dgcid=PromoSpots_EBDsite_Oralcancer. Last accessed February 19, 2024.
2. Management of Substance Use Disorders Work Group. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington, DC: Department of Veterans Affairs, Department of Defense; 2021. Available at https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf. Last accessed February 19, 2024.
Mention of commercial products does not indicate endorsement.